에 대한 최신 뉴스 UiPath (NYSE:PATH) 주식

UiPath

UiPath offers an end-to-end cross-application enterprise automation platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 혁신 분야에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다. 이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&amp;P 500과 비교

Equities

News

Markets

AVGO

목요일 거래 세션 동안 주요 미국 주식 지수는 노동 시장 둔화의 신호로 혼조세를 보였다. S&amp;P 500 지수는 0.3% 하락한 5,503.41로 마감되었고, 다우존스 산업평균지수는 0.5% 하락한 40,755.75로 마감되었다. 반면 나스닥 종합지수는 0.25% 상승한 17,127.66으로 거래를 마쳤다.

목요일 주목받은 주식 5종목: 브로드컴, 유아이패스, 니오, 삼사라, 테슬라

Earnings

Management

After-Hours Center

Movers

유아이패스(NYSE:PATH)는 목요일 시장 마감 후 2분기 재무 결과를 발표했다. 이 발표 이후 주가는 시간외 거래에서 9% 이상 상승했다. 이 보고서의 주요 내용은 다음과 같다.

유아이패스의 주식은 강력한 2분기 실적과 긍정적인 지침에 9% 이상 상승

UiPath Inc

Pathfinder Bancorp Inc

PATHFINDER CELL THERAPY by Pathfinder Cell Therapy, Inc.

Pathfinder Cell Therapy Inc

Pathfinder Ventures Inc

PATHFINDER VENTURES INC by PATHFINDER VENTURES INC.

Pathward Financial Inc

Ark Funds, led by Cathie Wood, is one of the most well-known fund managers thanks to its actively managed ETFs that focus on future growth <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41593922/cathie-woods-ark-invest-sees-tesla-unlocking-11-trillion-revenue-potential-with-rob">areas of innovation.</a>
Two of the fund's ETFs celebrate their 10th anniversaries on Thursday. Here's a look back at the funds' launch and how they've performed over the last 10 years.
Ark Innovation: Wood and<a href="https://www.benzinga.com/topic/ark-funds"> Ark Funds launched</a> the Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) on Oct. 31, 2014. The fund has grown to become the most well-known and largest of the company's funds, with $5.78 billion in assets under management.
"ARRK is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily in domestic and foreign equity securities of companies that are relevant to the Fund's investment theme of disruptive innovation," the company's <a href="https://www.ark-funds.com/funds/arkk">website </a>says.
Disruptive innovation themes include autonomous mobility, precision therapies, next gen cloud, neural networks, intelligent devices, digital wallets, digital assets, smart contracts and multiomic technologies, according to the company.
"ARK defines ‘disruptive innovation' as the introduction of a technologically enabled new product or service that potentially challenges the way the world works."
Here are the current top 10 holdings in the ARKK ETF and their percent of net assets:
<ol>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): 14.1%</li>
<li>Roku Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>): 10.8%</li>
<li>Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): 8.1%</li>
<li>Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>): 6.2%</li>
<li>Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>): 5.1%</li>
<li>Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): 5.0%</li>
<li>Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>): 4.9%</li>
<li>CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>): 4.5%</li>
<li>Shopify Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>): 3.9%</li>
<li>UiPath Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>): 2.9%</li>
</ol>
Since the fund's inception, the ETF is up 161.4%. This return trails the current 10-year return of the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500.
Here's a look at how the returns of ARKK stack up against SPY, which is the <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/10/41407647/spy-reaches-600-billion-in-assets-oldest-us-etf-hits-milestone-as-all-time-highs-conti">oldest and largest </a>U.S. ETF, over time:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Average Annual Returns</td>
<td>ARKK</td>
<td>SPY</td>
</tr>
<tr>
<td>1-Year</td>
<td>+19.9%</td>
<td>+36.2% </td>
</tr>
<tr>
<td>3-Year</td>
<td>-24.3%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5-Year</td>
<td>+2.6% </td>
<td>+15.8%</td>
</tr>
<tr>
<td>Since ARKK Inception 10/31/14</td>
<td>+10.2%</td>
<td>+13.2% </td>
</tr>
</tbody>
</table>
</figure>
The chart below from <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1">Benzinga Pro </a>shows the 10-year return of ARKK.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1003" height="513" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png" alt="" class="wp-image-624517" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png 1003w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-768x393.png 768w" sizes="(max-width: 1003px) 100vw, 1003px" /></a></figure>
For comparison, here is the 10-year chart of the SPY. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png" alt="" class="wp-image-624522" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-768x392.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Read Next: <a href="https://www.benzinga.com/markets/penny-stocks/23/08/34102486/exclusive-cathie-wood-tells-benzinga-why-tesla-should-trade-as-a-tech-stock">EXCLUSIVE: Cathie Wood Tells Benzinga Why Tesla Should Trade As A Tech Stock</a>
ARK Genomic: The Ark Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) was also launched by Ark Funds on Oct. 31, 2014. The fund currently has $1.33 billion in assets under management.
"ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy, and consumer discretionary, that are relevant to the Fund's investment theme of the genomics revolution," the company's <a href="https://www.ark-funds.com/funds/arkg">website </a>says.
Themes for the genomics ETF include precision therapies, multiomic technologies, programmable biology, neural networks, next gen cloud and adaptive robotics, according to the company.
Here are the current top 10 holdings in the ARKG ETF and their percent of net assets:
<ol>
<li>Twist Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>): 8.7%</li>
<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>): 7.0%</li>
<li>CRISPR Therapeutics: 7.0%</li>
<li>CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>): 5.1%</li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>): 4.7%</li>
<li>Veracyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYCT#NASDAQ">VYCT</a>): 4.6%</li>
<li>Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>): 4.3%</li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>): 4.1%</li>
<li>Natera Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>): 3.8%</li>
<li>10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>): 3.8%</li>
</ol>
Since the fund's inception, the ETF is up 38.9%. This return trails the current 10-year return of the SPDR S&amp;P 500 ETF Trust.
Here's a look at how the returns of ARKG stack up against SPY over time. &nbsp;
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Average Annual Returns</td>
<td>ARKG</td>
<td>SPY</td>
</tr>
<tr>
<td>1-Year</td>
<td>-7.9% </td>
<td>+36.2%</td>
</tr>
<tr>
<td>3-Year</td>
<td>-29.9%</td>
<td>+11.8% </td>
</tr>
<tr>
<td>5-Year</td>
<td>-1.9% </td>
<td>+15.8% </td>
</tr>
<tr>
<td>Since ARKG inception 10/31/14</td>
<td>+3.3%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
Here is the 10-year chart of ARKG. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="510" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png" alt="" class="wp-image-624525" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-768x394.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Why It's Important: The charts above show that ARKK and ARKG both experiences several years of strong growth and returns for investors, but have underperformed the broader S&amp;P 500 market index in recent years.
The ETFs were once among the most talked about funds, and the company&#8217;s daily trading activity often moved stocks higher, given Wood's outperformance years ago.
While the S&amp;P 500 ETF rebalances quarterly, the actively managed funds complete trades almost every day. Often, the average cost of shares rises over time for stocks that are going up, potentially hurting the gains.
Ark Funds typically invests in companies that it believes will have strong growth over the next five to ten years, which means the funds&#8217; returns can sometimes take years to pay off.
Wood has been early to many themes, including buying shares of NVIDIA Corporation for around $5 in 2014, before the most recent stock split. The fund later sold out of its position in late 2022 and early 2023 and<a href="https://www.benzinga.com/general/education/24/02/37294405/heres-how-much-cathie-wood-ark-invest-flagship-fund-missed-by-selling-nvidia-early"> missed out on huge gains </a>over the last nearly two years.
The fund manager was also early in the Tesla growth story, <a href="https://www.benzinga.com/news/22/03/26046331/if-you-invested-1-000-in-tesla-when-cathie-wood-made-her-4-000-prediction-heres-how-much-youd-have-n-1" target="_blank" rel="noopener">predicting a $4,000 price target</a> for the electric vehicle company back in February 2018. While Wood was laughed at for the price prediction at the time, the stock would hit the target on a split-adjusted basis in January 2021.
Getting the Tesla prediction right helped elevate Wood's status as a fund manager and led to increased interest in the Ark Funds ETFs.
Although interest in Ark Funds ETFs may have cooled in recent years, many investors still recall their impact and continue to track daily trading activity, watching closely which stocks Wood selects to hold for the next five to 10 years.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/23/08/34028505/exclusive-why-does-cathie-wood-think-bitcoin-is-going-to-1-million-what-does-she-know-that">EXCLUSIVE: Why Does Cathie Wood Think Bitcoin Is Going To $1 Million — What Does She Know That We Don&#8217;t?</a></li>
</ul>
Image courtesy of Ark Invest and Shutterstock.

Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500

As part of its comprehensive digital transformation strategy, Omega Healthcare uses the UiPath Platform, including the AI Trust Layer and security governance features, to securely optimize workflows, enhance business value, stimulate growth, and increase profit margins for its clients.&nbsp;

UiPath Says It Is Transforming Operations For Omega Healthcare Through AI-powered Automation

JP Morgan analyst Mark Murphy maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Overweight and lowers the price target from $19 to $17.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on UiPath, Lowers Price Target to $17

Wells Fargo analyst Michael Turrin maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Equal-Weight and lowers the price target from $15 to $13.

Wells Fargo Maintains Equal-Weight on UiPath, Lowers Price Target to $13

Analysts' ratings for UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) over the last quarter vary from bullish to bearish, as provided by 10 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $15.5, a high estimate of $18.00, and a low estimate of $14.00. Witnessing a positive shift, the current average has risen by 4.87% from the previous average price target of $14.78.
<img src="https://www.benzinga.com/files/images/story/2024/1729684889_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of UiPath's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to UiPath. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of UiPath compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for UiPath's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of UiPath's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PATH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on UiPath analyst ratings.</a>
<h2>All You Need to Know About UiPath</h2>
UiPath offers an end-to-end cross-application enterprise automation platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
<h3>Understanding the Numbers: UiPath's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining UiPath's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.07% as of 31 July, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: UiPath's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -27.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -4.46%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): UiPath's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.1%, the company may face hurdles in achieving optimal financial returns.
Debt Management: UiPath's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 10 Analysts Discuss UiPath Stock

10 analysts have expressed a variety of opinions on UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for UiPath, revealing an average target of $15.5, a high estimate of $18.00, and a low estimate of $14.00. Marking an increase of 4.87%, the current average surpasses the previous average price target of $14.78. 
<img src="https://www.benzinga.com/files/images/story/2024/1729684833_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive UiPath. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to UiPath. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of UiPath compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for UiPath's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into UiPath's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PATH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on UiPath analyst ratings.</a>
<h2>Discovering UiPath: A Closer Look</h2>
UiPath offers an end-to-end cross-application enterprise automation platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
<h3>Understanding the Numbers: UiPath's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, UiPath showcased positive performance, achieving a revenue growth rate of 10.07% as of 31 July, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: UiPath's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -27.22%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -4.46%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): UiPath's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.1%, the company may face hurdles in achieving optimal financial returns.
Debt Management: UiPath's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.05.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On UiPath Through 10 Analysts

Needham analyst Scott Berg reiterates UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Hold.

Reiteration

Needham Reiterates Hold on UiPath

UiPath's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) short percent of float has fallen 25.0% since its last report. The company recently reported that it has 23.76 million shares sold short, which is 5.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>UiPath Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728670512_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for UiPath has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing UiPath's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, UiPath's peer group average for short interest as a percentage of float is 4.90%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About UiPath?

Investors with a lot of money to spend have taken a bullish stance on UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PATH, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for UiPath.
This isn't normal.
The overall sentiment of these big-money traders is split between 62% bullish and 25%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $156,000, and 2 are calls, for a total amount of $106,400.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $12.5 to $25.0 for UiPath over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for UiPath's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of UiPath's whale activity within a strike price range from $12.5 to $25.0 in the last 30 days. 
<h3>UiPath 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728315069_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PATH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.69</td>
<td>$1.41</td>
<td>$1.41</td>
<td>$17.50</td>
<td>$56.4K</td>
<td>4.6K</td>
<td style="text-align: right;">500</td>
</tr>
<tr>
<td>PATH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$0.7</td>
<td>$0.4</td>
<td>$0.5</td>
<td>$25.00</td>
<td>$50.0K</td>
<td>5.4K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.74</td>
<td>$2.57</td>
<td>$2.6</td>
<td>$12.50</td>
<td>$26.0K</td>
<td>7.9K</td>
<td style="text-align: right;">938</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.82</td>
<td>$2.57</td>
<td>$2.6</td>
<td>$12.50</td>
<td>$26.0K</td>
<td>7.9K</td>
<td style="text-align: right;">638</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.7</td>
<td>$2.56</td>
<td>$2.6</td>
<td>$12.50</td>
<td>$26.0K</td>
<td>7.9K</td>
<td style="text-align: right;">538</td>
</tr>
</tbody>
</table>

<h3>About UiPath</h3>
UiPath offers an end-to-end cross-application enterprise automation platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
<h3>UiPath's Current Market Status</h3>
<ul>
<li>With a volume of 1,657,785, the price of PATH is down -2.2% at $12.21. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 53 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest UiPath options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

UiPath's Options Frenzy: What You Need to Know

Financial giants have made a conspicuous bearish move on UiPath. Our analysis of options history for UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) revealed 11 unusual trades.
Delving into the details, we found 18% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $666,810, and 5 were calls, valued at $225,186.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $10.0 to $12.5 for UiPath during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in UiPath's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to UiPath's substantial trades, within a strike price spectrum from $10.0 to $12.5 over the preceding 30 days.
<h3>UiPath Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727295350_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.65</td>
<td>$1.6</td>
<td>$1.65</td>
<td>$12.00</td>
<td>$445.7K</td>
<td>8.4K</td>
<td>5.0K</td>
</tr>
<tr>
<td>PATH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.8</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$10.00</td>
<td>$69.2K</td>
<td>0</td>
<td>188</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$1.64</td>
<td>$1.56</td>
<td>$1.6</td>
<td>$12.00</td>
<td>$64.0K</td>
<td>8.4K</td>
<td>2.0K</td>
</tr>
<tr>
<td>PATH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.6</td>
<td>$4.2</td>
<td>$4.6</td>
<td>$10.00</td>
<td>$50.5K</td>
<td>1.7K</td>
<td>165</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$1.64</td>
<td>$1.56</td>
<td>$1.6</td>
<td>$12.00</td>
<td>$48.0K</td>
<td>8.4K</td>
<td>2.3K</td>
</tr>
</tbody>
</table>

<h3>About UiPath</h3>
UiPath offers an end-to-end cross-application enterprise automation platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
Having examined the options trading patterns of UiPath, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of UiPath</h3>
<ul>
<li>With a volume of 5,485,144, the price of PATH is down -3.63% at $12.48. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 65 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for UiPath, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in UiPath

In the last three months, 11 analysts have published ratings on UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for UiPath, revealing an average target of $15.36, a high estimate of $18.00, and a low estimate of $14.00. This current average reflects an increase of 3.78% from the previous average price target of $14.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1725656441_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of UiPath among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to UiPath. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of UiPath compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of UiPath's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PATH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on UiPath analyst ratings.</a>
<h2>Delving into UiPath's Background</h2>
UiPath offers an end-to-end cross-application enterprise automation platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
<h3>A Deep Dive into UiPath's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: UiPath's revenue growth over a period of 3 months has been noteworthy. As of 30 April, 2024, the company achieved a revenue growth rate of approximately 15.72%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -8.58%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): UiPath's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.42%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): UiPath's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.99%, the company may face hurdles in achieving optimal financial performance.
Debt Management: UiPath's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 11 Analyst Insights On UiPath

UiPath, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) shares are down Friday, reversing from earlier strength after the company posted better-than-expected second-quarter financial results <a href="https://www.benzinga.com/news/earnings/24/09/40740923/uipath-reports-strong-q2-results-500m-share-repurchase-program-upbeat-guidance">after Thursday's closing bell.</a>
The Details:
UiPath beat analyst expectations on the top and bottom lines with revenue growth of more than 10% year-over-year. The company also announced a $500 million expansion to its share repurchase program and issued fiscal year revenue guidance above estimates.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/24/09/40733143/whats-going-on-with-celsius-holdings-stock">What&#8217;s Going On With Celsius Holdings Stock?</a>
Multiple analysts raised price targets on the stock following the print:&nbsp;
<ul>
<li>Barclays maintained UiPath with an Equal-Weight and raised its price target from $14 to $15.</li>
<li>BMO Capital analyst Keith Bachman maintained a Market Perform rating and raised the price target from $14 to $15.</li>
<li>B of A Securities analyst Brad Sills maintained a Neutral rating and raised the price target from $16 to $18.</li>
<li>Evercore ISI Group maintained UiPath with an In-Line rating and raised its price target from $13 to $16.</li>
<li>Wells Fargo analyst Michael Turrin maintained an Equal-Weight rating and raised the price target from $14 to $15.</li>
</ul>
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, UiPath shares have already surpassed the stock's average daily trading volume and 12.05% of shares are being sold short.&nbsp;
<h3 class="wp-block-heading">Will PATH Stock Go Up?</h3>
When trying to assess whether or not UiPath will trade higher from current levels, it's a good idea to take a look at analyst forecasts. 
Wall Street analysts have an average 12-month price target of $15.33 on UiPath. The Street high target is currently at $18 and the Street low target is $14. Of all the analysts covering UiPath, no one has positive ratings, 9 have neutral ratings and no one has negative ratings.
In the last month, 9 analysts have adjusted price targets. Here's a look at recent price target changes <a href="https://www.benzinga.com/quote/PATH/analyst-ratings">[Analyst Ratings]</a>. Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering UiPath have performed in recent history. 
Stocks don't move in a straight line. The average stock market return is approximately 10% per year. UiPath is 44.87% down year-to-date. The average analyst price target suggests the stock could have further upside ahead.
For a broad overview of everything you need to know about UiPath, visit <a href="https://www.benzinga.com/quote/PATH">here</a>. If you want to go above and beyond, there's no better tool to help you do just that than <a href="https://pro.benzinga.com/">Benzinga Pro</a>. Start your free trial today.
PATH Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, UiPath shares are down 5.11% at $12.09 at the time of publication Friday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40741553/us-judge-temporarily-blocks-bidens-latest-student-loan-relief-plan-why-it-matters">US Judge Temporarily Blocks Biden&#8217;s Latest Student Loan Relief Plan: Why It Matters</a></li>
</ul>
Image: Courtesy of UiPath, Inc.&nbsp;

What's Going On With UiPath Stock After Earnings?

DA Davidson analyst Gil Luria maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Neutral and raises the price target from $13 to $15.

DA Davidson Maintains Neutral on UiPath, Raises Price Target to $15

TD Cowen analyst Bryan Bergin maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Hold and lowers the price target from $17 to $16.

TD Cowen Maintains Hold on UiPath, Lowers Price Target to $16

Shares of UiPath Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) are down Friday despite the company&#8217;s reporting <a href="https://www.benzinga.com/markets/equities/24/09/40744060/broadcom-uipath-nio-samsara-tesla-why-these-5-stocks-are-on-investors-radars-today">in-line fiscal second-quarter results</a>.
Here are some key analyst takeaways:
<ul>
<li>BMO Capital Markets <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/585beadcb5a482000151d18b/keith-bachman">analyst Keith Bachman</a> maintained a Market Perform rating, while raising the price target from $14 to $15.</li>
<li>DA Davidson <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/60784b4c4853ea0001b62900/gil-luria">analyst Gil Luria</a> reaffirmed a Neutral rating, while lifting the price target from $13 to $15.</li>
<li>JPMorgan <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d5296ab85e930001416e5a/mark-murphy">analyst Mark Murphy</a> reiterated an Overweight rating and price target of $19.</li>
<li>RBC Capital Markets <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5880b6f377f9dd00011b0ab2/matthew-hedberg">analyst Matthew Hedberg</a> maintained a Sector Perform rating and price target of $16.</li>
<li>KeyBanc Capital Markets <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5af19c83ca26bd0001e8af36/jason-celino">analyst Jason Celino</a> reaffirmed a Sector Weight rating on the stock.KeyBanc Capital Markets </li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
BMO Capital Markets: UiPath's quarterly results were broadly in-line with low expectations, Bachman said in a note. This is a positive, after the previous quarter's execution challenges, amid a leadership change, he added.  
The company reported annual recurring revenues of $1.55 billion. This represents 19% year-on-year growth, but a deceleration of 2 points versus the prior quarter, the analyst stated. "We are encouraged by $850M cloud ARR, representing more than half of ARR and growing by 65% y/y, demonstrating PATH's cloud-first strategy is gaining traction," he further wrote.
DA Davidson: UiPath's fiscal second-quarter results "demonstrated early success in the company&#8217;s efforts to refocus on customer centricity," Luria said. The company raised its full-year adjusted operating income guidance from $145 million to $170 million.
"The company is laser-focused on cementing its reputation as the world&#8217;s leader in enabling actions from AI insight," the analyst wrote. UiPath had several enterprise wins and the net retention among its largest accounts remains at around 120%, he added.
JPMorgan: While there are macro uncertainties, overall conditions are stabilizing compared to the previous quarter, Murphy said. Better execution and streamlining efforts helped UiPath "adapt well to the current environment," he added.
The company indicated that "restructuring efforts primarily in its central functions, with a focus on sales operations and enablement, have enhanced efficiency and agility across the organization," the analyst wrote. Management announced "modest" raises to their full-year revenue and ARR guidance and "decent upticks for operating income and FCF guidance," he further stated.
RBC Capital Markets: UiPath showed "signs of stability," following a "sizable guide-down across the board," Hedberg said. Management raised their fiscal 2025 guidance by more than the beat. The company &#8220;continues to work towards its strategic initiatives," he added.
The company continues to focus on "realigning investments to higher ROI areas," adopting a stronger strategy for growth products, and focusing on expanding its channel partner relationships, the analyst stated. "Encouragingly, management highlighted strong early adoption and positive feedback from customers for Autopilot," he further wrote.
KeyBanc Capital Markets: UiPath reported quarterly revenue and operating margin at $316.3 million and 2%. It beat consensus of $303.7 million and 0.9%, respectively. Both gross retention and net retention declined in the quarter to 97% and 115%, from 98% and 118% in the previous quarter.
The company announced another share repurchase program of up to $500 million, the analyst stated. UiPath took its full-year guidance for operating income "meaningfully higher," implying operating margins of 12%, versus the Street estimates of 9.7%, , Celino wrote.
PATH Price Action: Shares of UiPath had declined by 5.34% to $12.06 at the time of publication on Friday.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40750261/wall-street-sighs-in-relief-as-august-jobs-numbers-ease-recession-fears-small-caps-outperform-doll">Wall Street Sighs In Relief As August Jobs Numbers Ease Recession Fears: Small Caps Outperform, Dollar Trims Weekly Losses</a></li>
</ul>
Image courtesy of UiPath, Inc.

Analyst Color

Earnings Beats

UiPath Q2 Results Reflect Restructuring Benefits, Analysts Praise 'Laser-Focus' On AI

Morgan Stanley analyst Keith Weiss assumes UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Equal-Weight rating and announces Price Target of $15.

Initiation

Morgan Stanley Assumes UiPath at Equal-Weight, Announces Price Target of $15

RBC Capital analyst Matthew Hedberg reiterates UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Sector Perform and maintains $16 price target.

RBC Capital Reiterates Sector Perform on UiPath, Maintains $16 Price Target

Barclays analyst Raimo Lenschow maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Equal-Weight and raises the price target from $14 to $15.

Barclays Maintains Equal-Weight on UiPath, Raises Price Target to $15

Wells Fargo analyst Michael Turrin maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Equal-Weight and raises the price target from $14 to $15.

Wells Fargo Maintains Equal-Weight on UiPath, Raises Price Target to $15

Evercore ISI Group analyst Kirk Materne maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a In-Line and raises the price target from $13 to $16.

Evercore ISI Group Maintains In-Line on UiPath, Raises Price Target to $16

In a report released today, Raimo Lenschow from Barclays maintained a Hold rating on UiPath (PATH – Research Report), with a price target of $15.00...

UiPath (PATH) Receives a Hold from Barclays

In a report released today, Kirk Materne from Evercore ISI maintained a Hold rating on UiPath (PATH – Research Report), with a price target of $16....

Evercore ISI Sticks to Their Hold Rating for UiPath (PATH)

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on WEX (WEX – Research Report), Western Digital (WDC ...

Analysts Offer Insights on Technology Companies: WEX (WEX), Western Digital (WDC) and UiPath (PATH)

UiPath: Buy For Strong Recovery Potential, Future Enterprise AI Growth

Analysts have been eager to weigh in on the Technology sector with new ratings on CCC Intelligent Solutions Holdings (CCCS – Research Report), Cade...

Analysts Offer Insights on Technology Companies: CCC Intelligent Solutions Holdings (CCCS), Cadence Design (CDNS) and UiPath (PATH)

Bullish option flow detected in UiPath (PATH) with 11,964 calls trading, 4x expected, and implied vol increasing over 2 points to 45.25%. 11/8 week...

UiPath call volume above normal and directionally bullish

With robust demand, and the need for higher efficiency, the SAAS market is poised for continued growth and expansion. Therefore, it could be ideal to closely monitor high-growth SAAS stocks UiPath (PATH), CCC Intelligent Solutions (CCCS), and DocuSign (DOCU) for substantial benefit. Read on... The popularity of Software-as-a-Service (SAAS) is rapidly surging among organizations to boost their efficiency and adopt the latest technologies. SAAS has emerged as a prominent force in the technology and business landscape, and this trend is set to continue further as organizations deploy and use software.
Given the industry's strong outlook, investors could consider high-growth SAAS stocks UiPath Inc. (<a href="https://stocknews.com/stock/PATH/">PATH</a>), CCC Intelligent Solutions Holdings Inc. (<a href="https://stocknews.com/stock/CCCS/">CCCS</a>), and DocuSign, Inc. (<a href="https://stocknews.com/stock/DOCU/">DOCU</a>) in November.
With the rapid transformation from traditional software applications to cloud-based software services, the Software-as-a-service market is poised to expand exponentially. Companies are increasingly investing in digital transformation and adopting trends like Vertical SaaS, DaaS, and iPaaS in order to boost their operational efficiency, cost-effectiveness, and versatility.
<a href="https://www.gartner.com/en/newsroom/press-releases/2024-05-20-gartner-forecasts-worldwide-public-cloud-end-user-spending-to-surpass-675-billion-in-2024#:~:text=SaaS%20spending%20is%20projected%20to,consumption%20model%2C%E2%80%9D%20said%20Nag.">Gartner projected worldwide end-user spending</a> on public cloud services to increase by 20.4%, reaching $675.4 billion this year, driven by generative AI (GenAI) and application modernization.
Also, SaaS continues to dominate the cloud market in end-user spending, having a projection of 20% growth in spending to reach $247.2 billion in 2024.
Following these lucrative trends, the global Software as a Service (SaaS) market is expected to grow from $317.55 billion in 2024 to $1.23 billion by 2032, exhibiting growth at a <a href="https://www.fortunebusinessinsights.com/software-as-a-service-saas-market-102222">CAGR of 18.4%</a>. In global comparison, the U.S. SaaS market is anticipated to grow to $236.69 billion by 2032, driven by the adoption of public and hybrid cloud-based tools.
With growing needs, companies engaged in SAAS services are positioned to capitalize on the industry's bright prospects and will yield high growth in the long run. Thus, investors could scoop up high-growth SaaS companies' stocks to advance their portfolios.
Now, let's take a closer look at the fundamentals of the top <a href="https://stocknews.com/category/software-saas/">Software - SAAS</a> stocks mentioned above, beginning with the third choice.
Stock #3: UiPath Inc. (<a href="https://stocknews.com/stock/PATH/">PATH</a>)
PATH provides an end-to-end automation platform offering a diverse range of international robotic process automation (RPA) solutions. It provides a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
On October 22, PATH announced a strategic partnership with Inflection AI to integrate the UiPath Platform with the new Inflection for Enterprise solution, enabling enterprises to achieve greater levels of operational efficiency and effectiveness without compromising trust and AI security options.
The strategic partnership will integrate Inflection AI within UiPath Autopilot and provide an important private cloud alternative for agentic automation tailored to the industries.
On October 15, PATH announced the integration of the UiPath Platform with the SAP Build Process Automation solution, to be sold as one of the SAP Solution Extensions. The offering will enable true enterprise-wide transformation by allowing customers to embrace a holistic view of automation across heterogeneous environments that span both SAP and non-SAP systems.
For the second that ended July 31, 2024, PATH's total revenue increased 10.1% year-over-year to $316.25 million. Its non-GAAP <a href="https://www.investopedia.com/terms/g/grossprofit.asp#:~:text=Gross%20profit%2C%20or%20gross%20income,fluctuate%20compared%20to%20production%20output.">gross profit</a> grew 6.6% from the year-ago value to $263.18 million. Also, the company's non-GAAP net income amounted to $23.76 million or $0.04 per share for the quarter, respectively.
Furthermore, as of July 31, 2024, the company's non-GAAP adjusted free cash flow was $149.78 million.
Analysts expect PATH's revenue and EPS for the fiscal year (ending January 2026) to increase 11.3% and 10.5% year-over-year to $1.58 billion and $0.44, respectively. Further, the company has topped the consensus revenue and EPS estimates in all four trailing quarters.
PATH's stock has surged 3.1% over the past three months to close the last trading session at $12.70.
PATH's solid outlook is reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Growth and Quality. Within the A-rated <a href="https://stocknews.com/category/software-saas/">Software - SAAS</a> industry, PATH is ranked #11 among 18 stocks.
<a href="https://stocknews.com/stock/PATH/">Click here</a> to access additional ratings of PATH (Stability, Value, Sentiment, and Momentum).
Stock #2: CCC Intelligent Solutions Holdings Inc. (<a href="https://stocknews.com/stock/CCCS/">CCCS</a>)
CCCS operates as a software-as-a-service company for the property and casualty insurance economy. Its cloud-based SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, artificial intelligence-enabled digital workflow across the insurance economy.
On September 4, CCCS launched CCC&#xAE; Payroll, a new solution designed to streamline payroll management for collision repair shops. CCC Payroll is integrated into the CCC ONE&#xAE; platform and enables shops to track production and labor and streamline payroll within a single system, simplifying the payroll process.
The new solution simplifies the payroll process and gives greater visibility to employees.
On July 30, CCCS unveiled CCC&#xAE; Intelligent Reinspection, a new solution designed to help auto insurers streamline the review of incoming repair facility estimates, expediting repairer workflows and claims resolutions. The new solution leverages AI technology, and identifies areas for review, and provides reason codes based on insurer rules, helping reinspectors.
For the third quarter that ended on September 30, 2024, CCCS' revenues increased 7.8% year-over-year to $238.48 million. Its adjusted gross profit rose 8% from the prior year's period to $185.93 million. The company's adjusted operating income of $91.19 million reflects growth of 10.3% from the previous year's quarter.
Furthermore, the company's adjusted net income stood at $62.58 million and $0.10 per share, up 9.5% and 11.1% year-over-year, respectively. Its adjusted EBITDA increased 9.3% from the year-ago value to $101.55 million.
Analysts expect CCCS' revenue for the fourth quarter (ending December 2024) to increase 7.3% year-over-year to $245.23 million. For the same period, its EPS is expected to grow 8% year-over-year to $0.10. Further, the company topped the consensus revenue and EPS estimates in all trailing four quarters, which is remarkable.
Over the past year, the stock has gained 2.3% to close the last trading session at $10.93.
CCCS' sound fundamentals are reflected in its POWR Ratings. The stock has an overall grade of A, translating to a Strong Buy in our proprietary rating system.
CCCS has a B grade for Momentum, Stability, Sentiment, and Growth. It is ranked #4 among the 18 stocks within the A-rated Software - SAAS industry.
To see the other ratings of CCCS for Quality and Value, <a href="https://stocknews.com/stock/CCCS/">click here</a>.
Stock #1: DocuSign, Inc. (<a href="https://stocknews.com/stock/DOCU/">DOCU</a>)
DOCU provides electronic signature solutions internationally. The company provides an e-signature solution, enabling the sending and signing of agreements on various devices, Contract Lifecycle Management (CLM), Document Generation streamlines the process of generating new, custom agreements, and Gen for Salesforce.
On June 4, DOCU launched a new connector for SAP Ariba solutions that automate workflows between Docusign CLM and SAP Ariba solutions to help businesses accelerate time to value and eliminate friction in source-to-pay agreement processes. The launch enhanced DOCU's market position and firmly established the company as a leader.
On May 31, DOCU acquired Lexion, a leading AI-powered agreement management company. The acquisition strengthened DOCU's position in Intelligent Agreement Management (IAM) and added more AI-assisted capabilities to its platform, bringing more insights, analysis, and automation to its customers.
DOCU's total revenues increased 7% year-over-year to $736.03 million during the second quarter that ended on July 31, 2024. It reported non-GAAP income from operations of $237.16 million, indicating growth of 39.6% year-over-year. The company's non-GAAP free cash flow grew 7.8% from the year-ago value to $197.93 million.
Additionally, the company's non-GAAP net income came in at $200.99 million and $0.97 per share, up 34.3% and 34.7% from the prior year's quarter, respectively.
According to the company's fiscal year 2025 outlook, DOCU expects total revenue between $2.94 billion and $2.95 billion, while it forecasts subscription revenue to range from $2.86 billion to $2.88 billion.
For the third quarter (ending October 2024), analysts expect DOCU's revenue to grow 6.4% year-over-year to $745.32 million. For the same period, the company's EPS is expected to increase 10.6% year-over-year to $0.87. Also, it has surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
DOCU's stock has surged 22.9% over the past six months and 80.9% over the past year to close the last trading session at $70.15.
DOCU's POWR Ratings reflect its promising prospects. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system.
DOCU has an A grade for Quality and a B grade for Growth and Value. It is ranked #2 among 18 stocks in the same industry.
In addition to the POWR Ratings I've just highlighted, you can see DOCU's ratings for Stability, Momentum, and Sentiment <a href="https://stocknews.com/stock/DOCU/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
DOCU shares were trading at $68.98 per share on Wednesday afternoon, down $1.17 (-1.67%). Year-to-date, DOCU has gained 16.03%, versus a 23.16% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/docu-path-cccs-3-high-growth-saas-stocks-to-watch-in-november/>3 High-Growth SaaS Stocks to Watch in November</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 High-Growth SaaS Stocks to Watch in November

Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2024 Update

ARKB

ARKF

ARKQ

ARKW

ARKX

BEAM

CCCS

CDNS

DKNG

DOCU

NTLA

Press Releases

UiPath to Host Investor Session at FORWARD + TechEd 2024 in Las Vegas

UiPath Recognizes Global Winners of 2024 Partner Awards at FORWARD Conference

UiPath and Inflection AI Announce Partnership to Bring Agentic AI to Security-Focused Industries

UiPath Unveils New Vision for the Future: Expanding the Boundaries of AI with Agentic Automation

UiPath Integrates Anthropic Claude Language Models to Deliver Next Generation AI Assistant and Solutions

UiPath Announces 2024 AI25 Award Winners

Française des Jeux Achieves Significant Efficiency Gains with UiPath's AI-Powered Automation

Banco Azteca Achieves Massive Cost Savings and Speeds Digital Transformation with UiPath AI and Automation

Omega Healthcare Processes 60 Million Transactions with Enterprise AI and Automation from UiPath

Deluxe Named UiPath AI25 Award Winner

Appian Corporation - Class A Common Stock

Appian

CrowdStrike Holdings, Inc. - Class A Common Stock

CrowdStrike Holdings

CommVault Systems

Dolby Laboratories

JFrog

Fortinet

Gen Digital

GitLab

Monday.Com

Microsoft

N-able

ServiceNow

Oracle

OneStream

Palo Alto Networks

Progress Software Corporation - Common Stock

Progress Software

Qualys

Rubrik

Rapid7

SentinelOne

Teradata

Tenable Holdings

Varonis Systems

Zscaler

JP Morgan

Wells Fargo

BMO Capital

DA Davidson

TD Cowen

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41593922/cathie-woods-ark-invest-sees-tesla-unlocking-11-trillion-revenue-potential-with-rob" target="_blank" rel="noopener" data-google-interstitial="false">혁신 분야</a>에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다.
이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.
아크 이노베이션: 우드와 <a href="https://www.benzinga.com/topic/ark-funds">아크 펀드</a>는 Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 2014년 10월 31일에 출시했다. 이 펀드는 이 회사의 가장 유명하고 가장 큰 펀드로 성장했으며, 현재 57억 8천만 달러의 운용 자산을 보유하고 있다.
&#8220;ARRK는 자본의 장기적 성장을 추구하는 액티브하게 관리되는 ETF로, 일반적으로 국내 및 해외 주식에 주로 투자하여 펀드의 투자 테마인 파괴적 혁신(disruptive innovation)와 관련된 회사들에 투자한다&#8221;고 이 회사의 <a href="https://www.ark-funds.com/funds/arkk">웹사이트</a>에서 설명한다.
파괴적 혁신 테마에는 자율 이동성, 정밀 치료, 차세대 클라우드, 신경망, 지능형 기기, 디지털 지갑, 디지털 자산, 스마트 계약 및 멀티오믹 기술이 포함된다.
&#8220;ARK는 &#8216;파괴적 혁신&#8217;을 세상이 돌아가는 방식에 잠재적으로 도전할 수 있는 기술적으로 구현된 새로운 제품이나 서비스의 도입으로 정의한다.&#8221;
현재 ARKK ETF의 상위 10개 보유 종목과 그 순자산 비율은 다음과 같다:
<ol>
<li>테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): 14.1%</li>
<li>로쿠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>): 10.8%</li>
<li>코인베이스 글로벌 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): 8.1%</li>
<li>로블록스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>): 6.2%</li>
<li>팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>): 5.1%</li>
<li>로빈후드 마켓 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): 5.0%</li>
<li>블록 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>): 4.9%</li>
<li>크리스퍼 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>): 4.5%</li>
<li>쇼피파이 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>): 3.9%</li>
<li>유아이패스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>): 2.9%</li>
</ol>
이 펀드 설립 이래로 이 ETF의 수익률은 161.4% 상승했다. 이 수익률은 S&amp;P 500을 추적하는 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)의 현재 10년 수익률에는 미치지 못한다.
아래의 표는 ARKK의 수익률이 SPY와 어떻게 비교되는지를 보여준다. SPY는 <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/10/41407647/spy-reaches-600-billion-in-assets-oldest-us-ETF-hits-milestone-as-all-time-highs-conti">가장 오래되고 가장 큰</a> 미국 ETF이다:
<figure class="wp-block-table">
<table>
<tbody>
<tr>
<td>평균 연간 수익률</td>
<td>ARKK</td>
<td>SPY</td>
</tr>
<tr>
<td>1년</td>
<td>+19.9%</td>
<td>+36.2%</td>
</tr>
<tr>
<td>3년</td>
<td>-24.3%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5년</td>
<td>+2.6%</td>
<td>+15.8%</td>
</tr>
<tr>
<td>ARKK 설립 이래 2014년 10월 31일 기준</td>
<td>+10.2%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
아래의 차트는 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1">Benzinga Pro</a>에서 제공한 ARKK의 10년 수익률을 보여준다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png" sizes="(max-width: 1003px) 100vw, 1003px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png 1003w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-768x393.png 768w" alt="" width="1003" height="513" /></a></figure>
비교를 위해 SPY의 10년 차트도 보여드리겠다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png" sizes="(max-width: 995px) 100vw, 995px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-768x392.png 768w" alt="" width="995" height="508" /></a></figure>
다음 읽어보기: <a href="https://www.benzinga.com/markets/penny-stocks/23/08/34102486/exclusive-cathie-wood-tells-benzinga-why-tesla-should-trade-as-a-tech-stock">독점: 캐시 우드가 테슬라가 기술 주식으로 거래되어야 하는 이유를 Benzinga에 말했다.</a>
아크 지노믹스: Ark Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)는 2014년 10월 31일에 아크 펀드에 의해 출시되었다. 현재 이 ETF 펀드는 13억 3천만 달러의 자산을 운용하고 있다.
&#8220;ARKG는 자본의 장기적 성장을 추구하는 액티브하게 관리되는 ETF로, 일반적으로 헬스 케어, 정보 기술, 소재, 에너지 및 소비재 등 여러 섹터의 국내외 주식에 주로 투자하며, 펀드의 투자 테마인 유전체 혁명(genomics revolution)과 관련된 회사들에 투자한다&#8221;고 이 회사의 <a href="https://www.ark-funds.com/funds/arkg">웹사이트</a>에서 설명한다.
이 유전체 혁명 ETF의 테마에는 정밀 치료, 멀티오믹 기술, 프로그래머블 생물학, 신경망, 차세대 클라우드 및 적응형 로보틱스가 포함된다.
현재 ARKG ETF의 상위 10개 보유 종목과 그 순자산 비율은 다음과 같다:
<ol>
<li>트위스트 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>): 8.7%</li>
<li>리커젼 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>): 7.0%</li>
<li>크리스퍼 테라퓨틱스: 7.0%</li>
<li>케어Dx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>): 5.1%</li>
<li>어댑티브 바이오테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>): 4.7%</li>
<li>베라사이트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYCT#NASDAQ">VYCT</a>): 4.6%</li>
<li>아이오니스 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>): 4.3%</li>
<li>누릭스 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>): 4.1%</li>
<li>나테라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>): 3.8%</li>
<li>10x 지노믹스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>): 3.8%</li>
</ol>
이 펀드 설립 이래로 이 ETF의 수익률은 38.9% 상승했다. 이 수익률은 현재 SPDR S&amp;P 500 ETF Trust의 10년 수익률에는 미치지 못한다.
ARKG의 수익률이 SPY와 어떻게 비교되는지를 살펴보겠다.
<figure class="wp-block-table">
<table>
<tbody>
<tr>
<td>평균 연간 수익률</td>
<td>ARKG</td>
<td>SPY</td>
</tr>
<tr>
<td>1년</td>
<td>-7.9%</td>
<td>+36.2%</td>
</tr>
<tr>
<td>3년</td>
<td>-29.9%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5년</td>
<td>-1.9%</td>
<td>+15.8%</td>
</tr>
<tr>
<td>ARKG 설립 이래 2014년 10월 31일 기준</td>
<td>+3.3%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
다음은 ARKG의 10년 차트다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624525" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png" sizes="(max-width: 993px) 100vw, 993px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-768x394.png 768w" alt="" width="993" height="510" /></a></figure>
중요성 (Why It&#8217;s Important): 위의 차트들은 ARKK와 ARKG가 모두 투자자들에게 몇 년 동안 강력한 성장과 수익률을 경험했지만, 최근 몇 년 동안은 더 넓은 S&amp;P 500 시장 지수를 하회한 것을 보여준다.
한때 이 ETF들은 가장 화제가 된 펀드들 중 하나였으며, 이 회사의 일일 거래 활동은 종종 주식을 상승시켰다. 이는 우드의 뛰어난 성과 덕분이다.
S&amp;P 500 ETF는 분기마다 리밸런싱을 하지만, 이 액티브하게 관리되는 펀드는 거의 매일 거래를 완료한다. 종종 주가가 상승하는 주식의 평균 매입가가 시간이 지남에 따라 상승하여 수익률에 부정적인 영향을 미칠 수 있다.
아크 펀드는 일반적으로 향후 5년에서 10년 동안 강력한 성장을 할 것으로 믿는 회사들에 투자한다. 이는 펀드의 수익률이 때때로 몇 년이 걸려야 나타날 수 있음을 의미한다.
우드는 엔비디아의 주식을 2014년에 약 5달러에 매수한 것과 같이 많은 테마에 대해 일찍 투자한 바 있다. 이는 가장 최근의 주식 분할 이전의 일이었다. 이 펀드는 나중에 2022년 말과 2023년 초에 이 포지션에서 완전히 매도하여 지난 2년 가까이 <a style="font-size: revert;" href="https://www.benzinga.com/general/education/24/02/37294405/heres-how-much-cathie-wood-ark-invest-flagship-fund-missed-by-selling-nvidia-early">엄청난 수익을 놓쳤</a>다.
이 펀드 매니저는 또한 테슬라 성장 스토리에 일찍 투자했다. 2018년 2월에 이 전기차 회사에 대해 $4,000 목표 주가를 <a href="https://www.benzinga.com/news/22/03/26046331/if-you-invested-1-000-in-tesla-when-cathie-wood-made-her-4-000-prediction-heres-how-much-youd-have-n-1" target="_blank" rel="noopener">예측</a>했다. 당시에는 가격 예측으로 비웃음거리가 되었지만, 주가는 2021년 1월에 분할 기준으로 목표 주가에 도달했다.
테슬라에 대한 예측이 맞아들어간 것은 우드의 펀드 매니저로서의 위상을 높이는 데 도움이 되었고, 아크 펀드 ETF들에 대한 관심이 증가하는 계기가 되었다.
최근 몇 년 동안 아크 펀드 ETF들에 대한 관심이 식었지만, 많은 투자자들은 여전히 그들의 영향을 기억하고 일일 거래 활동을 계속 추적하며, 우드가 향후 5년에서 10년 동안 보유할 주식을 주의 깊게 지켜보고 있다.

다음 읽어보기:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/23/08/34028505/exclusive-why-does-cathie-wood-think-bitcoin-is-going-to-1-million-what-does-she-know-that">독점: 캐시 우드는 왜 비트코인이 100만 달러에 이를 것이라고 생각하는가? 그녀는 무엇을 알고 있기에?</a></li>
</ul>
이미지 제공: Ark Invest 및 Shutterstock.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&P 500과 비교

목요일 거래 세션 동안 주요 미국 주식 지수는 <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40728795/private-employment-grows-by-99-000-in-august-sharply-misses-forecasts-of-140-000-">노동 시장 둔화</a>의 신호로 혼조세를 보였다. S&amp;P 500 지수는 0.3% 하락한 5,503.41로 마감되었고, 다우존스 산업평균지수는 0.5% 하락한 40,755.75로 마감되었다. 반면 나스닥 종합지수는 0.25% 상승한 17,127.66으로 거래를 마쳤다.
이들은 하루 동안 소매 거래자와 투자자들의 주목을 받은 주요 종목들이다:
브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)
브로드컴의 주식은 0.84% 하락하여 $152.82에 마감되었으며, 장중 최고가와 최저가는 각각 $156.36과 $150.11이었다. 52주 최고가와 최저가는 각각 $185.16과 $79.54이다. 이 반도체 거인은 <a href="https://kr.benzinga.com/news/usa/stocks/%eb%b8%8c%eb%a1%9c%eb%93%9c%ec%bb%b4%ec%9d%98-%ec%a3%bc%ec%8b%9d%ec%9d%80-%ec%96%91%ed%98%b8%ed%95%9c-3%eb%b6%84%ea%b8%b0-%ec%8b%a4%ec%a0%81%ec%97%90%eb%8f%84-%ec%98%88%ec%83%81%eb%b3%b4%eb%8b%a4/" target="_blank" rel="noopener">강력한 3분기 재무 결과</a>를 발표하며 인공 지능(AI) 솔루션과 VM웨어(VMware)의 지속적인 강세를 보였다.
유아이패스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>)
유아이패스의 주식은 0.16% 상승하여 $12.74에 마감되었다. 주식은 장중 최고가와 최저가가 각각 $12.8과 $12.44였으며, 52주 범위는 $27.87에서 $10.37이다. 이 회사는 강력한 2분기 실적을 발표하고 <a href="https://kr.benzinga.com/news/usa/stocks/%ec%9c%a0%ec%95%84%ec%9d%b4%ed%8c%a8%ec%8a%a4%ec%9d%98-%ec%a3%bc%ec%8b%9d%ec%9d%80-%ea%b0%95%eb%a0%a5%ed%95%9c-2%eb%b6%84%ea%b8%b0-%ec%8b%a4%ec%a0%81%ea%b3%bc-%ea%b8%8d%ec%a0%95%ec%a0%81%ec%9d%b8/" target="_blank" rel="noopener">5억 달러 규모의 자사주 매입 프로그램</a>을 발표했다.
참고: <a href="https://www.benzinga.com/markets/equities/24/09/40723060/jim-cramer-tries-to-quell-investor-fears-amid-nvidia-selloff-if-you-have-a-market-thats-been-dri?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">짐 크레이머가 엔비디아 매도세 속에서 투자자 우려를 잠재우려 합니다: &#8216;소수의 주식에 의해 주도가 된 시장이 있다면…&#8217;</a>
니오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>)
니오의 주식은 14.39% 상승하여 $4.85에 마감되었다. 주식의 장중 최고가와 최저가는 각각 $4.85와 $4.27였으며, 52주 범위는 $10.91에서 $3.61이다. 니오의 주식은 강력한 2분기 재무 실적 발표 후 급등하였으며, 이는 전년 대비 98.9% 매출 성장과 개선된 총 마진을 보여주었다. 이 회사는 <a href="https://www.benzinga.com/news/24/09/40733121/why-nio-shares-are-trading-today" target="_blank" rel="noopener" data-google-interstitial="false">3분기 추가 성장</a>을 예측하며, 차량 인도량과 매출 증가를 예상했다.
삼사라(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>)
삼사라의 주식은 0.23% 상승하여 $38.75에 마감되었다. 장중 최고가와 최저가는 각각 $39.35와 $37.85였으며, 52주 범위는 $42.49에서 $21.48이다. 이 회사는 <a href="https://kr.benzinga.com/news/usa/stocks/%ec%82%bc%ec%82%ac%eb%9d%bc%ec%9d%98-%ec%a3%bc%ec%8b%9d%ec%9d%80-%ec%98%88%ec%83%81%eb%b3%b4%eb%8b%a4-%ec%a2%8b%ec%9d%80-2%eb%b6%84%ea%b8%b0-%ec%8b%a4%ec%a0%81%ea%b3%bc-%ec%97%b0%ea%b0%84-%ec%a7%80/" target="_blank" rel="noopener">2분기 재무 실적</a>이 예상보다 좋게 나타나 주가가 상승했다.
테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라의 주식은 4.90% 상승하여 $230.17에 마감되었다. 주식은 장중 최고가와 최저가가 각각 $235와 $222.25였으며, 52주 범위는 $278.97에서 $138.8이다. 테슬라는 사이버트럭을 위한 <a href="https://www.benzinga.com/news/24/09/40716748/tesla-shares-are-trading-higher-today-whats-going-on">3,000달러의 겨울 타이어 패키지</a>를 출시하여 눈이 많이 오는 조건에서의 성능 우려를 해결했으며, 생산을 확대하고 있다. 이 움직임은 테슬라가 전기차 시장에서의 영향력을 확대함에 따라 추운 기후 고객들을 겨냥한 것이다.
사진 출처: WHYFRAME, Shutterstock
벤징가와 함께 <a href="Premarket Movers &amp; News">상위 프리마켓 이동자 및 뉴스</a>로 하루의 거래를 준비하세요.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40681461/nancy-pelosis-stock-pick-broadcom-poised-for-breakout-after-recent-consolidation-she-never-loses?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">낸시 펠로시의 주식 선택 Broadcom 최근 보합 이후 돌파 준비: &#8216;그녀는 절대 지지 않는다&#8217;고 소셜 미디어 사용자</a></li>
</ul>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

유아이패스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>)는 목요일 시장 마감 후 2분기 재무 결과를 발표했다. 이 발표 이후 주가는 시간외 거래에서 9% 이상 상승했다. 이 보고서의 <a href="https://www.benzinga.com/pressreleases/24/09/b40740202/uipath-reports-second-quarter-fiscal-2025-financial-results" target="_blank" rel="noopener" data-google-interstitial="false">주요 내용</a>은 다음과 같다.
주요 내용: 유아이패스는 분기별 주당 순이익(EPS)을 4센트로 보고했는데, 이는 애널리스트들의 예상치인 3센트를 웃도는 수치이다. 분기별 매출은 3억 1,625만 달러로 분석가의 합의 추정치인 3억 367만 달러를 넘어섰으며 지난해 같은 기간에 비해 10.07% 증가한 수치이다.
<ul>
<li>ARR(연간 반복 매출)는 15억 5,100만 달러로 전년 대비 19% 증가했다.</li>
<li>순 새로운 ARR은 4,300만 달러이다.</li>
<li>달러 기반 순 유지율은 115%이다.</li>
<li>비 GAAP 기준 총 이익률은 83%이다.</li>
</ul>
유아이패스는 자사 주식 매입 프로그램을 5억 달러 확대한다고 발표했다. 또한 아심 굽타(Ashim Gupta)가 즉시 CFO의 역할 외에 COO로서의 역할도 확대 맡게 될 것이라고 발표했다.
&#8220;우리는 ARR이 전년 대비 19% 성장한 2분기 결과에 만족한다. 이는 팀의 향상된 실행력과 AI 기반 자동화 플랫폼이 고객에게 제공하는 강력한 가치에 대한 증거이다&#8221;고 유아이패스의 CEO인 다니엘 다인스(Daniel Dines)가 말했다.
"고객 및 파트너와의 대화를 통해 인공지능(AI)와 자동화에 대한 필요성이 점점 더 커지고 있다는 확신이 깊어졌고, 혁신에 대한 우리의 확고한 의지는 우리를 AI가 기업에 제공하는 기회를 포착하기 위해 선택하는 자동화 플랫폼으로 계속 자리매김하고 있다."
다음 읽기: <a href="https://www.benzinga.com/news/24/09/40733143/whats-going-on-with-celsius-holdings-stock">셀시우스 홀딩스 주식에 무슨 일이 일어나고 있나요?</a>
전망: 유아이패스는 3분기 매출이 추정치 3억 4,724만 달러 대비 3억 4,500만 ~ 3억 5,000만 달러, 회계 연도 매출이 추정치 14억 1천만 달러 대비 14억 2,000만 ~ 14억 2,500만 달러로 예상된다.
PATH 주가 움직임.: <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>에 따르면 유아이패스의 주식은 목요일 애프터 아워 거래에서 9.50% 상승하여 13.95달러로 거래되었다.
사진: UiPath, Inc. 제공
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

세일즈포스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>)는 운영을 간소화하기 위해 약 300명의 역할을 축소한 것으로 알려졌으며, 이는 기술 업계가 비용 관리에 지속적으로 초점을 맞추고 있음을 강조한다.
<a href="https://www.bloomberg.com/news/articles/2024-07-15/salesforce-cuts-about-300-jobs-in-latest-sign-of-tech-austerity" target="_blank" rel="noreferrer noopener">블룸버그</a>는 이 문제에 정통한 gks 소식통을 인용해 회사가 이번 달 인력을 감축했다고 보도했다. 성명서에서 세일즈포스는 일자리 감소를 확인했지만 이 보도에 따라 구체적인 내용은 제공하지 않았다.
이 보도는 대변인을 인용해 &#8220;다른 건강한 기업과 마찬가지로 우리는 고객에게 가장 좋은 서비스를 제공하고 성장 영역을 촉진할 수 있는 올바른 구조가 있는지 지속적으로 평가한다&#8221;라고 말했다. &#8220;어떤 경우에는 역할이 제거되는 경우도 있다.&#8221;
세일즈포스는 2023년에 직원을 10% 또는 <a href="https://www.benzinga.com/news/24/01/36798167/salesforce-cuts-700-jobs-in-streamlining-effort-yet-eyes-growth-with-1-000-open-roles" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">약 8,000명</a> 줄인 데 이어 2024년 1월 전체 인력 70,000명 중 약 1%인 약 700명을 해고했다.
1월 말 기준, 세일즈포스의 글로벌 총 직원은 72,682명으로 집계됐다.
세일즈포스의 주식은 지난 12개월 동안 10% 이상 상승했습니다. 투자자는 Vanguard S&amp;P 500 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) 및 Vanguard Total Stock Market ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>)를 통해 주식에 노출될 수 있다.
여러 기술 회사들은 이번 달에 인튜이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>)가 약 1,800명의 직원을 해고하고 <a href="https://www.benzinga.com/markets/equities/24/07/39713891/why-software-company-intuits-shares-are-trading-lower-today" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">보이시 및 에드먼턴 사이트</a>를 폐쇄하는 등 인원 감축을 발표했다.
또한 지난 7월 유아이패스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>)는 인력 10% 감축을 포함하여 운영 비용 관리를 위한 구조 조정 조치 계획을 공개했다.
또 다른 기술 대기업인 마이크로소프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)는 또 다른 정리해고를 실시하여 <a href="https://www.benzinga.com/markets/equities/24/07/39632988/microsoft-carries-out-another-round-of-layoffs-across-teams-and-geographies-third-this-year-so-f" target="_blank" rel="noreferrer noopener">다양한 팀과 지역에 영향</a>을 미쳤다.
특히 <a href="https://www.benzinga.com/markets/equities/24/01/36874447/tech-layoffs-up-over-300-month-over-month-in-january-3-companies-with-the-most-employees-laid-of" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2023년 12월에 비해</a> 2024년 1월 기술 부문에서 해고된 직원 수가 304% 증가했다.
주가 움직임: 화요일 현재 <a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">세일즈포스</a>의 주식은 개장 전 거래에서 0.02% 하락한 252.81달러를 기록했다.
면책조항: 이 콘텐츠는 AI 도구의 도움으로 부분적으로 제작되었으며 Benzinga 편집자가 검토하고 게시했습니다.
Photo via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Large Cap

Media

INTU

MSFT

세일즈포스, 기술 침체 속에서 300명의 일자리를 줄이고 비용 통제 강조: 보도

유아이패스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>)는 수요일 시장 마감 후 1분기 재무 결과를 보고하고 최고 경영자(CEO) 변경을 발표했다. 이 보고서의 <a href="https://www.benzinga.com/pressreleases/24/05/b39073161/uipath-reports-first-quarter-fiscal-2025-financial-results">세부 내용</a>을 살펴보자. 이 회사는 로보틱 처리 자동화 소프트웨어를 만드는 글로벌 소프트웨어 기업이다.
주요 정보 (The Details): 유아이패스는 분기별 주당 순이익을 13센트로 보고했는데, 이는 애널리스트 컨센서스인 12센트를 8.33% 앞선 것이다.
분기별 매출은 3억 3,500만 달러로 분석가 컨센서스 추정치 3억 3,304만 달러를 넘어섰고, 이는 지난해 같은 기간 매출 2억 8,959만 달러보다 15.68% 증가한 수치이다.
이 회사는 전년 대비 21% 증가한 15억 8천만 달러의 ARR을 보고했으며, 운영 현금 흐름은 1억 달러, 비GAAP 조정 잉여 현금 흐름은 1억 100만 달러를 기록했다.
"우리는 2025회계연도 1분기에 ARR이 15억 달러를 넘어섰다는 사실을 보고하게 되어 기쁘게 생각한다. 이는 시장을 선도하는 비즈니스 자동화 플랫폼과 자동화가 디지털 혁신에서 수행하는 전략적 역할에 대한 증거이다"고 유아이패스의 창립자이자 최고 혁신책임자인 다니엘 다인스(Daniel Dines)가 말했다.
&#8220;우리는 우리 사업의 기반이 여전히 탄탄하다고 믿으며 향상된 실행, 고객 중심, 지속적인 혁신을 통해 성장과 수익성을 추진할 수 있는 능력에 대해 낙관하고 있다.&#8221;
또한 이 회사는 롭 엔슬린(Rob Enslin)이 2024년 6월 1일부터 CEO직을 사임하고 유아이패스 이사회 구성원이 될 것이라고 <a href="https://www.benzinga.com/pressreleases/24/05/b39073158/uipath-to-re-appoint-daniel-dines-as-chief-executive-officer-rob-enslin-steps-down-as-ceo-and-boar">발표</a>했다. 유아이패스의 창립자이자 전 CEO인 다니엘 다인스가 역시 2024년 6월 1일부터 CEO로 재임명될 예정이다.
전망 (Outlook): 유아이패스는 2분기 매출을 3억~3억 500만 달러, 2025회계연도 매출을 14억 5,000만~14억 1,000만 달러로 예상하고 있다.
관련 뉴스:<a href="https://www.benzinga.com/news/24/05/39071154/whats-going-on-with-amc-entertainment-stock-today"> AMC 엔터테인먼트의 거래량 급증 속 특정 종목의 움직임 (NYSE:</a><a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>)
PATH 주가 움직임: <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">벤징가 프로</a>에 따르면, 수요일 유아이패스의 주식은 시간외 거래에서 29.02% 급락한 12.99달러를 기록했다.
이미지: UiPath, Inc. 소유

유아이패스: 양호한 1분기 실적에도 CEO 변경과 약한 2분기 전망 발표 후 주식 급락

화요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 어드밴스드 마이크로 디바이시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), 팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) 및 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)와 관련된 중요한 거래를 했다. 이러한 거래는 시장 움직임에 따른 아크의 전략적 조정을 반영한다.
AMD 거래
아크는 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)를 통해 AMD 주식 7,861주를 매입했다. 이 거래 금액은 135만 달러에 달했다. 화요일에 이 칩 제조업체의 주가는 3.2% 상승한 171.61달러에 마감했다.
AMD는 차세대 프로세서를 준비하고 GPU 로드맵을 공개하면서 서버 CPU 시장에서 33%의 점유율을 차지했다고 주장했다. 최고 재무책임자(CFO) 장 후(Jean Hu)는 파트너십과 AMD 기반 인프라로의 전환을 언급하면서 <a href="https://www.benzinga.com/news/24/05/39037776/amd-grabs-33-of-server-cpu-market-and-prepares-for-major-processor-launch-report">서버, CPU 및 GPU</a>의 강력한 성장을 강조했다. 분석가들은 어려움에도 불구하고 반도체 산업이 낙관적일 것으로 예상한다.
팔란티어 거래
아크 인베스트의 ARK Space Exploration &amp; Innovation ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) 펀드는 205,721달러 상당의 팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) 주식 9,773주를 인수했다. ARKX를 통해 주식을 매입하려는 이러한 움직임은 정밀 조사를 받고 있는 팔란티어의 최근 주식 실적 이후에 나온 것이다. Benzinga 보고서에 따르면 팔란티어는 <a href="https://www.benzinga.com/news/earnings/24/05/38737083/whats-going-on-with-palantirs-stock">시장의 상황과 투자자의 심리</a>로 인해 등락을 경험해 왔다. 화요일에 팔란티어의 주가는 0.2% 상승한 21.05달러로 마감했다.
모더나 거래
같은 날 아크 인베스트의 ARK Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)와 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) 펀드는 총 28,670주의 모더나 주식을 매각했다. 이 주식은 종가 153.20달러에 매각되었으며 총 가치는 약 440만 달러에 달한다. 매도 결정은 화요일 모더나 주가가 8.05% <a href="https://www.benzinga.com/news/24/05/39046064/whats-going-on-with-moderna-stock-today" target="_blank" rel="noopener">하락한</a> 후에 나온 것이다.
또 다른 <a href="https://www.benzinga.com/news/large-cap/24/05/39022913/moderna-was-among-the-best-performing-large-cap-stocks-last-week-may-20-may-26-2024-are-they-in-yo" target="_blank" rel="noopener">Benzinga</a> 보도에 따르면 이번 매도는 전문가들이 여름에 코로나19 감염이 증가할 것으로 예측하면서 지난주 가장 실적이 좋은 대형주 중 하나로 부각된 모더나의 최근 실적에 따른 것이다.
다른 중요한 거래들:
<ul>
<li>ARKK가 유니티 소프트웨어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) 주식을 매각</li>
<li>ARKK가 유아이패스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) 주식을 매입하고 ARKW가 누 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) 주식을 매각</li>
<li>ARKK가 로블록스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) 주식을 매입</li>
</ul>
다음 내용 읽기: <a href="https://kr.benzinga.com/news/%ec%97%94%eb%b9%84%eb%94%94%ec%95%84%eb%8a%94-%ed%85%8c%ec%8a%ac%eb%9d%bc-%ec%97%91%ec%8a%a8-%ec%9b%94%eb%a7%88%ed%8a%b8-%ec%bd%94%ec%8a%a4%ed%8a%b8%ec%bd%94-%eb%84%b7%ed%94%8c%eb%a6%ad%ec%8a%a4/" target="_blank" rel="noopener">엔비디아의 시가총액, 테슬라, 엑슨, 월마트, 코스트코, 넷플릭스, 인텔, 디즈니, 펩시보다 높아</a>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>가 제작하였으며 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집했습니다.

MRNA

아크 인베스트가 AMD와 팔란티어 주식을 매수하며, 모더나 주식을 매도

월요일, 캐시 우드가 이끄는 아크 인베스트가 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) 및 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)가 포함된 중요한 거래를 진행했다.
코인 거래
아크 인베스트는 ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) 펀드에서 코인베이스의 주식 3,689주를 처분하기로 결정했다. 월요일 223.41달러의 종가를 기준으로 COIN 주식의 가치는 약 82.4만 달러이다.
비록 지난주 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 가격이 상승했지만, 아크 인베스트는 일정한 날들에 연속해서, <a href="https://www.benzinga.com/markets/equities/24/04/38214834/cathie-woods-ark-invest-sells-20m-coinbase-shares-as-bitcoin-trades-over-70k-buys-palantir-sells">상당량의 코인베이스 주식을 팔</a>았다.
NVDA 거래
아크 투자는 또한 ARK 유전체 혁명(Genomic Revolution) ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) 펀드에서 엔비디아 주식 157주를 처분했다. 월요일 860.01달러의 종가를 기준으로 엔비디아 주식의 가치는 약 13만 5천 달러이다. 이러한 움직임은 NVIDIA가 또 다른 상승세를 보일 준비가 되어 있다고 <a href="https://www.benzinga.com/markets/equities/24/04/38235114/nvidia-set-for-another-bull-run-analyst-pitches-1-150-target-says-this-time-its-br">예측한</a> 차트 분석가의 최근 낙관적인 예측에도 불구하고 나온 것이다.
다른 주요 거래:
<ul>
<li>아크 인베스트는 ARKF, ARKG 및 ARKK 펀드에서 텔라닥 헬스(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/tdoc" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for TDOC">TDOC</a>)의 주식을 매수했다. ARKG 펀드에서는 유아이패스(UiPath Inc) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>)의 주식을 매도했다.</li>
<li>ARKK 펀드에서는 로쿠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>)의 주식을 매수하고 드래프트킹스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>)의 주식을 팔았다.</li>
<li>ARKW 펀드는 트윌리오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>)의 주식을 팔았다.</li>
</ul>
다음 읽어보기: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38237724/dogecoin-co-creator-billy-markus-sarcastically-signals-caution-amid-cryptocurrency-market-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">도지코인 공동 창시자 빌리 마르커스, 암호화폐 시장 추락 속에서 비꼬아 경고 신호: &#8220;앗 안녕 모두 다 죽었어요&#8221;</a>

<div style="font-family: 'Lato', sans-serif;">
<hr style="border: 0; height: 5px; background: #225aa9;" />
<div style="background-color: #f5f5f5; background-position: center; background-size: cover; justify-content: center;"></div>
<a style="color: #225aa9; text-decoration: none;" href="None" target="_blank" rel="noopener">데이타</a>를 통한 내용생성으로, 당사는 실시간으로 포괄적인 이야기를 전달할 수 있습니다.
<hr style="border: 0; height: 1px; background: #225aa9;" />
<a style="color: #225aa9; text-decoration: none;" href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener">더 알아보기</a>
<hr style="border: 0; height: 5px; background: #225aa9;" />
</div>

$BTC

NVDA

TDOC

TWLO

캐시 우드의 아크 인베스트가 코인베이스와 엔비디아 주식을 계속 매각

목요일, 캐시 우드의 아크 인베스트(Ark Invest)는 변동하는 시장 상황과 전략적 투자 결정을 배경으로 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), 팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) 및 엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)를 포함한 중요한 거래를 진행했다.
COIN 거래
비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 가격이 최근 상승하고 있음에도 불구하고, 아크 인베스트는 ARK 이노베이션 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK 넥스트 제너레이션 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)에서 코인베이스를 77,561주를 팔았다. 이 거래의 액수는 263.01달러의 최종 종가에 기초하여 약 20.34백만 달러이다.
하루 전에는 24,141주에 해당하는 606만달러 가치의 <a href="https://www.benzinga.com/markets/equities/24/04/38195354/cathie-wood-led-ark-invest-continues-to-sell-coinbase-shares-despite-uptick-in-bitcoin-loads-up-">코인베이스 주식을 매도</a>하기도 했다. 이때는 코인베이스 주식과 비트코인 상승했다. 기사 작성 당시, 비트코인은 24시간 동안 0.2% 하락한 70,000달러를 넘기는 가격으로 거래되고 있다.
PLTR 거래
같은 날, 아크 인베스트는 팔란티어 주식을 매수했다. 이러한 움직임은 아크가 챗GPT의 모회사인 오픈AI의 <a href="https://www.benzinga.com/markets/mutual-funds/24/04/38213342/cathie-wood-ark-invest-announce-stake-in-openai-heres-how-you-can-get-exposure-to-chatgpt-pa">최근 지분 매수</a>와 관련있다. 이 거래의 가치는 22.84달러의 최종 종가를 기초로하여 162,232달러이다.
NVDA 거래
참고: <a href="https://www.benzinga.com/markets/equities/24/04/38161049/jim-cramer-feels-very-good-about-ford-as-jim-farley-led-company-is-making-a-come-back?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer, 포드에 대해 &#8216;매우 좋은&#8217; 느낌</a>
아크 인베스트는 인공지능 분야의 주요 기업 중 하나인 엔비디아 주식 또한 팔았다. 이 결정은 해당 주식에 대한 <a href="https://www.benzinga.com/markets/equities/24/04/38154787/cathie-woods-ark-sheds-nearly-4m-nvidia-shares-and-trims-position-in-this-ai-peer">지속적인 기대에도</a> 불구하고 내려졌다. NVDA 거래 금액은 최종 종가인 906.16달러를 기준으로 255만 달러이다.
기타 주요 거래:
<ul>
<li>아크 인베스트는 텔러닥(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) 주식을 매수했다.</li>
<li>아크 인베스트는 유아이패스(UiPath Inc.)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) 주식을 매도했다. 아크 인베스트는 리커전 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) 주식을 매입했다.</li>
</ul>
차기 내용: <a href="https://www.benzinga.com/markets/equities/24/04/38175804/jim-cramer-stands-by-nvidia-and-eli-lilly-despite-market-dips-says-terrific-time-to-take-some-pr?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer, 시장 하락에도 Nvidia와 Eli Lilly를 지지한다며 &#8216;이익을 낼 수 있는 즐거운 시간&#8217;</a>

<div style="font-family: 'Lato', sans-serif;">
<hr style="border: 0; height: 5px; background: #225aa9;" />
<div style="background-color: #f5f5f5; background-position: center; background-size: cover; justify-content: center;"></div>
<hr style="border: 0; height: 1px; background: #225aa9;" />
<hr style="border: 0; height: 5px; background: #225aa9;" />
</div>

Comments

UiPath

뉴스

에 대한 최신 뉴스 UiPath (NYSE:PATH) 주식

금요일, 11월 01, 2024

금요일, 9월 06, 2024

목요일, 9월 05, 2024

화요일, 7월 16, 2024

수요일, 5월 29, 2024

화요일, 4월 16, 2024

금요일, 4월 12, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌